Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lactic Acid→

Lactic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-21-5
Molecular formula
C3H6O3
Molecular weight
90.08 g/mol
Drug class
Alpha-hydroxy acidTopical humectant and keratolytic agent
Mechanism of action
Lactic acid is an alpha-hydroxy acid. In topical formulations it may act as a humectant and reduce corneocyte cohesion; the precise mechanism of these skin effects is not fully established.
Indications / reported uses
  • Topical treatment of ichthyosis vulgaris and xerosis in ammonium-lactate formulations

Sources: DailyMed — Ammonium lactate cream: lactic acid pharmacology and labelled uses

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lactic Acid Environmental Risk Assessment (ERA) (the Lactic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.